|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5350836A
(en)
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
WO1992015602A1
(en)
|
1991-02-28 |
1992-09-17 |
Dana-Farber Cancer Institute, Inc. |
Cancer diagnosis and therapy
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
US5288931A
(en)
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
WO1994010187A1
(en)
|
1992-10-30 |
1994-05-11 |
Hsc Research And Development Limited Partnership |
COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
|
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
US7592428B1
(en)
|
1992-11-17 |
2009-09-22 |
Ludwig Institute For Cancer Research |
Antibodies which bind specifically to activin receptor like kinases
|
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
CA2149441C
(en)
|
1992-11-17 |
2004-03-02 |
Kohei Miyazono |
Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
|
|
EP0690871A4
(en)
|
1993-01-12 |
1999-10-20 |
Univ Johns Hopkins Med |
GROWTH DIFFERENTIATION FACTOR-5
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
|
CA2229557A1
(en)
|
1995-08-14 |
1997-02-27 |
Creative Biomolecules, Inc. |
Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
|
|
US6190660B1
(en)
|
1996-05-31 |
2001-02-20 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
|
|
JP4318752B2
(ja)
|
1996-05-31 |
2009-08-26 |
ヘルス・リサーチ・インコーポレーテッド |
抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
EP0998561A4
(en)
|
1997-07-15 |
2004-08-18 |
Immunex Corp |
RECEPTOR DES TRAIL PROTEIN
|
|
AU3092899A
(en)
|
1998-03-13 |
1999-09-27 |
Ludwig Institute For Cancer Research |
Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US20030012792A1
(en)
|
1998-05-22 |
2003-01-16 |
Holaday John W. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
US6413513B1
(en)
|
1998-05-22 |
2002-07-02 |
Entremed, Inc. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
JP2003509011A
(ja)
*
|
1999-06-03 |
2003-03-11 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
脈管形成タンパク質およびそれらの使用
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
JP3663382B2
(ja)
|
2000-02-15 |
2005-06-22 |
スージェン・インコーポレーテッド |
ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
|
|
US7077836B2
(en)
|
2000-07-21 |
2006-07-18 |
Vein Rx, Inc. |
Methods and apparatus for sclerosing the wall of a varicose vein
|
|
EP1392333A2
(en)
|
2000-08-03 |
2004-03-03 |
The University of Utah Research Foundation |
Manipulation of arterial-venous identity
|
|
DE10043481A1
(de)
|
2000-09-04 |
2002-04-11 |
Vectron Therapeutics Ag Imt |
Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
|
|
BR0116452A
(pt)
|
2000-12-21 |
2003-09-30 |
Glaxo Group Ltd |
Composto, composição farmacêutica, uso de um composto
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
KR100996226B1
(ko)
|
2001-10-31 |
2010-11-24 |
유니버시티 오브 노스 텍사스 헬스 사이언스 센터 |
뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
|
|
WO2003064628A2
(en)
|
2002-02-01 |
2003-08-07 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
|
US7045534B2
(en)
*
|
2002-02-12 |
2006-05-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of reducing angiogenesis
|
|
WO2003093293A2
(en)
|
2002-04-29 |
2003-11-13 |
Saint Louis University |
Peptide antagonists of tgf-beta family members and therapeutic uses thereof
|
|
AU2003247828B2
(en)
|
2002-06-27 |
2010-05-20 |
University Of Utah Research Foundation |
Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
|
|
AU2003287444A1
(en)
|
2002-10-31 |
2004-05-25 |
The General Hospital Corporation |
Repairing or replacing tissues or organs
|
|
WO2005010049A2
(en)
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
WO2005044849A2
(en)
|
2003-08-05 |
2005-05-19 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
EP1721257A2
(en)
|
2004-01-27 |
2006-11-15 |
Compugen Ltd. |
Differential expression of markers in ovarian cancer
|
|
EP1740609A2
(en)
|
2004-04-27 |
2007-01-10 |
Research Development Foundation |
Antagonism of tgf-beta superfamily receptor signaling
|
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
|
JP2008507288A
(ja)
*
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
WO2006091930A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Massachusetts Eye & Ear Infirmary |
Methods and compounds for promoting vessel regression
|
|
EP1861425B1
(en)
*
|
2005-03-10 |
2012-05-16 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
NZ566774A
(en)
*
|
2005-09-07 |
2011-11-25 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
JP2009534035A
(ja)
|
2006-04-21 |
2009-09-24 |
ワイス |
細胞系のハイスループットスクリーニング方法
|
|
WO2007143023A1
(en)
|
2006-05-31 |
2007-12-13 |
Beth Israel Deaconess Medical Center |
Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
|
|
US10059756B2
(en)
|
2006-11-02 |
2018-08-28 |
Acceleron Pharma Inc. |
Compositions comprising ALK1-ECD protein
|
|
US8642031B2
(en)
|
2006-11-02 |
2014-02-04 |
Acceleron Pharma, Inc. |
Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
|
|
CN111518218A
(zh)
*
|
2006-11-02 |
2020-08-11 |
阿塞勒隆制药公司 |
Alk1受体和配体拮抗剂及其用途
|
|
KR20100090683A
(ko)
|
2007-11-09 |
2010-08-16 |
제넨테크, 인크. |
액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
|
|
JP5719766B2
(ja)
|
2008-05-02 |
2015-05-20 |
アクセルロン ファーマ， インコーポレイテッド |
血管新生および周皮細胞組成物を調節するための方法および組成物
|
|
CA2724525A1
(en)
|
2008-05-15 |
2009-11-19 |
Acceleron Pharma, Inc. |
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
|
|
EP2364371A4
(en)
|
2008-11-24 |
2012-05-02 |
Univ Loma Linda |
BIOMARKER FOR DETECTING HEADS AND HALSTUMORS
|
|
WO2010128158A1
(en)
|
2009-05-08 |
2010-11-11 |
Novartis Ag |
Diagnostic biomarkers for fibrotic disorders
|
|
AU2012212047A1
(en)
|
2011-02-03 |
2013-08-22 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
WO2013116781A1
(en)
|
2012-02-02 |
2013-08-08 |
Acceleron Pharma Inc. |
Alk1 antagonists and their uses in treating renal cell carcinoma
|
|
US20140193425A1
(en)
|
2012-10-05 |
2014-07-10 |
Acceleron Pharma, Inc. |
Treatment of cancer with alk1 antagonists
|
|
WO2015147908A1
(en)
|
2014-03-28 |
2015-10-01 |
Acceleron Pharma, Inc. |
Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
|